{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009416","form_type":"8-K","ticker":null,"cik":"0001029125","company_name":"Panbela Therapeutics, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.153255+00:00","generated_at":"2026-06-04T07:34:32.886187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Panbela Q4 net loss $6.5M; ASPIRE trial >50% enrolled; cash $2.6M","bullets":["Net loss of $6.5M ($65.90/share) in Q4 2023 vs. $4.7M loss in Q4 2022.","Cash $2.6M at Dec 31, 2023; raised ~$9M in Jan 2024 registered offering.","ASPIRE Phase III trial for metastatic pancreatic cancer exceeds 50% enrollment; full enrollment (~600 patients) expected Q1 2025.","Research and development expense $6.1M in Q4, up from $3.5M year-over-year.","Divestiture of pediatric neuroblastoma program to US WorldMeds for up to $9.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009416","json":"https://secwatch.observer/filing/0001437749-24-009416.json","markdown":"https://secwatch.observer/filing/0001437749-24-009416.md","text":"https://secwatch.observer/filing/0001437749-24-009416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/0001437749-24-009416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/pbla20240326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:34:32.886187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2fd185db7001f912c77701f0e307f724132e5b5","claim":"Panbela Therapeutics, Inc. reported the quarter and full year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, EPS $65.90 per diluted share.","evidence_excerpt":"Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, compared to a net loss of $4.7 million, or $344.61 per diluted share, in the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/0001437749-24-009416-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share"},{"label":"EPS","value":"$65.90 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}